COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02805218
Recruitment Status : Completed
First Posted : June 17, 2016
Last Update Posted : June 20, 2016
Information provided by (Responsible Party):
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Brief Summary:
The purpose of this study is to estimate the safety and efficacy of PEG-rhG-CSF in patients with lymphoma receiving chemotherapy.

Condition or disease Intervention/treatment Phase
Lymphoma Drug: PEG-rhG-CSF Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 410 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy
Study Start Date : September 2013
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: PEG-rhG-CSF
patients received a single dose of 100 ug/kg of PEG-rhG-CSF(pegfilgrastim), on the basis of actual body weight, as a single subcutaneous injection on day 3 after chemotherapy
Drug: PEG-rhG-CSF
Other Name: pegfilgrastim

Primary Outcome Measures :
  1. The occurrence rate of adverse event [ Time Frame: up to 30 days after the patient study completion ]
  2. The severity of adverse event [ Time Frame: up to 30 days after the patient study completion ]

Secondary Outcome Measures :
  1. the occurrence rate of grade III/ IV neutropenia during chemotherapy cycles [ Time Frame: through the study completion,an average of 5 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with age ≥ 18 years
  • diagnosis of lymphoma(Hodgkin's lymphoma and non-Hodgkin's lymphoma) patients
  • Karnofsky Performance Status Z70
  • life expectancy of at least 8 months
  • normal white blood cell count and platelet count
  • Written informed consent are acquired

Exclusion Criteria:

  • uncontrolled infection
  • pregnancy
  • Have accepted any other anti-tumor drug within 4 weeks before anticipated the study
  • Other situations that investigators consider as contra-indication for this study
Layout table for additonal information
Responsible Party: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Identifier: NCT02805218    
Other Study ID Numbers: CSPC-PGC-IV-02-1
First Posted: June 17, 2016    Key Record Dates
Last Update Posted: June 20, 2016
Last Verified: June 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases